Assembly Biosciences, Inc. (NASDAQ:ASMB) Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Assembly Biosciences, Inc. (NASDAQ ASMB) traded up $1.67 during midday trading on Friday, reaching $30.25. 142,723 shares of the company’s stock traded hands, compared to its average volume of 110,692.

COPYRIGHT VIOLATION NOTICE: “Assembly Biosciences, Inc. (ASMB) Director William R. Ringo Sells 1,000 Shares” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/11/03/assembly-biosciences-inc-asmb-director-william-r-ringo-sells-1000-shares.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in Assembly Biosciences by 21.2% in the 2nd quarter. Vanguard Group Inc. now owns 610,916 shares of the biopharmaceutical company’s stock worth $12,615,000 after purchasing an additional 107,065 shares during the last quarter. State Street Corp acquired a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $4,234,000. Northern Trust Corp boosted its position in shares of Assembly Biosciences by 221.2% during the 2nd quarter. Northern Trust Corp now owns 195,321 shares of the biopharmaceutical company’s stock valued at $4,033,000 after acquiring an additional 134,513 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Assembly Biosciences during the 2nd quarter valued at about $3,426,000. Finally, Lyon Street Capital LLC boosted its position in shares of Assembly Biosciences by 352.6% during the 2nd quarter. Lyon Street Capital LLC now owns 136,200 shares of the biopharmaceutical company’s stock valued at $2,813,000 after acquiring an additional 106,107 shares in the last quarter. Institutional investors own 72.41% of the company’s stock.

Several analysts have issued reports on the stock. BidaskClub upgraded shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.